BillionToOne Inc.
Overview
BillionToOne Inc. develops single molecule diagnostics technology, including a non-invasive prenatal test and liquid biopsy tests for cancer, using proprietary Quantitative Counting Templates (QCTs™) to measure sparse disease-causing DNA fragments.
Therapeutic areas
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to BillionToOne Inc. in our records. PharmaTek screens the full directory against live FDA enforcement data.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.